Nucleic acid-based marker approaches to urologic cancers

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 6, 2006, Pages 510-527

  Veltri, Robert W ^a   Makarov, Danil V ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Epigenetic signatures; Genetic signatures; Molecular markers; Nucleic acid markers; Oncology; Urology

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; CADHERIN 6; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; DNA; ENZYME; MACROPHAGE SPECIFIC RECEPTOR 1; NUCLEIC ACID; PLAKOGLOBIN; POLYMERASE GAMMA; PROTEIN; RIBONUCLEASE L; SURVIVIN; TELOMERASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME 12P; CHROMOSOME 14Q; CHROMOSOME DELETION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOTHERAPY; KIDNEY CANCER; MARKER GENE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; NEPHRECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TELOMERE; TESTIS CANCER; URINARY TRACT CANCER; X CHROMOSOME;

CARCINOMA; HUMANS; KIDNEY NEOPLASMS; MALE; NUCLEIC ACIDS; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 33751347839     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2006.07.002     Document Type: Review

References (152)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
2. Carr K.M., Rosenblatt K., Petricoin E.F., et al. Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy. Hum Genomics 1 (2004) 134-140
3. Rountree M.R., Bachman K.E., Herman J.G., et al. DNA methylation, chromatin inheritance, and cancer. Oncogene 20 (2001) 3156-3165
4. Fearon E.R. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Intern Med 39 (1994) 123-147
5. Knudson A.G. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1 (2001) 157-162
6. Fearon E.R. A genetic basis for the multi-step pathway of colorectal tumorigenesis. Princess Takamatsu Symp 22 (1991) 37-48
7. Vogelstein B., and Kinzler K.W. The multistep nature of cancer. Trends Genet 9 (1993) 138-141
8. Jones P.A., and Takai D. The role of DNA methylation in mammalian epigenetics. Science 293 (2001) 1068-1070
9. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene 21 (2002) 5400-5413
10. Holth L.T., Chadee D.N., Spencer V.A., et al. Chromatin, nuclear matrix and the cytoskeleton: Role of cell structure in neoplastic transformation. (review). Int J Oncol 13 (1998) 827-837
11. Jain K.K. Personalized medicine for cancer: From drug development into clinical practice. Expert Opin Pharmacother 6 (2005) 1463-1476
12. Hood L., Heath J.R., Phelps M.E., et al. Systems biology and new technologies enable predictive and preventative medicine. Science 306 (2004) 640-643
13. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
14. Soh S., Kattan M.W., Berkman S., et al. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?. J Urol 157 (1997) 2212-2218
15. Carter H.B. PSA and the natural course of prostate cancer. In: Schröder F.H. (Ed). Recent advances in prostate cancer and BPH: The proceedings of the IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV), held in Rotterdam, the Netherlands, April 1996 (1997), Parthenon, New York (NY) 187-195
16. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin 51 (2001) 15-36
17. Stamey T.A., Donaldson A.N., Yemoto C.E., et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 160 (1998) 2412-2417
18. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
19. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
20. Millikan R., and Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology (Williston Park) 11 (1997) 180-193
21. Brenner S., Johnson M., Bridgham J., et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat Biotechnol 18 (2000) 630-634
22. Brown P.O., and Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 21 (1999) 33-37
23. Valasek M.A., and Repa J.J. The power of real-time PCR. Adv Physiol Educ 29 (2005) 151-159
24. Mundle S.D., and Sokolova I. Clinical implications of advanced molecular cytogenetics in cancer. Expert Rev Mol Diagn 4 (2004) 71-81
25. Montironi R., Mazzucchelli R., and Scarpelli M. Molecular techniques and prostate cancer diagnostic. Eur Urol 44 (2003) 390-400
26. Carpten J.D., Makalowska I., Robbins C.M., et al. A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region. Genomics 64 (2000) 1-14
27. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30 (2002) 181-184
28. Nelson W.G., De Marzo A.M., and Isaacs W.B. Prostate cancer. N Engl J Med 349 (2003) 366-381
29. Schaid D.J. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 1 (2004) R103-R121
30. Casey G., Neville P.J., Plummer S.J., et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32 (2002) 581-583
31. Nakazato H., Suzuki K., Matsui H., et al. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 89 (2003) 691-696
32. Noonan-Wheeler F.C., Wu W., Roehl K.A., et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate 66 (2005) 49-56
33. Xu J., Zheng S.L., Hawkins G.A., et al. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23. Am J Hum Genet 69 (2001) 341-350
34. Xu J., Zheng S.L., Komiya A., et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32 (2002) 321-325
35. Xu J., Zheng S.L., Komiya A., et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet 72 (2003) 208-212
36. Rennert H., Zeigler-Johnson C.M., Addya K., et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 14 (2005) 949-957
37. DeMarzo A.M., Nelson W.G., Isaacs W.B., et al. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
38. Moyzis R.K., Buckingham J.M., Cram L.S., et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 85 (1988) 6622-6626
39. Allsopp R.C., Chang E., Kashefi-Aazam M., et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 220 (1995) 194-200
40. Donaldson L., Fordyce C., Gilliland F., et al. Association between outcome and telomere DNA content in prostate cancer. J Urol 162 (1999) 1788-1792
41. Fordyce C.A., Heaphy C.M., Joste N.E., et al. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 173 (2005) 610-614
42. Meeker A.K., Hicks J.L., Iacobuzio-Donahue C.A., et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 10 (2004) 3317-3326
43. Loberg R.D., Fridman Y., Pienta B.A., et al. Detection and isolation of circulating tumor cells in urologic cancers: A review. Neoplasia 6 (2004) 302-309
44. Shay J.W., and Wright W.E. Telomerase activity in human cancer. Curr Opin Oncol 8 (1996) 66-71
45. Meid F.H., Gygi C.M., Leisinger H.J., et al. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol 165 (2001) 1802-1805
46. Lin Y., Uemura H., Fujinami K., et al. Detection of telomerase activity in prostate needle-biopsy samples. Prostate 36 (1998) 121-128
47. Botchkina G.I., Kim R.H., Botchkina I.L., et al. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res 11 (2005) 3239-3243
48. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
49. de Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695-2698
50. Hessels D., Klein Gunnewiek J.M., van Oort I., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-15
51. Glinsky G.V., Glinskii A.B., Stephenson A.J., et al. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113 (2004) 913-923
52. Stephenson A.J., Smith A., Kattan M.W., et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104 (2005) 290-298
53. Glinsky G.V., Berezovska O., and Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115 (2005) 1503-1521
54. Bastian P.J., Yegnasubramanian S., Palapattu G.S., et al. Molecular biomarker in prostate cancer: The role of CpG island hypermethylation. Eur Urol 46 (2004) 698-708
55. Li L.C., Carroll P.R., and Dahiya R. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 97 (2005) 103-115
56. Hayes J.D., and Pulford D.J. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30 (1995) 445-600
57. Lee W.H., Isaacs W.B., Bova G.S., et al. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 6 (1997) 443-450
58. Harden S.V., Sanderson H., Goodman S.N., et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 95 (2003) 1634-1637
59. Bastian P.J., Palapattu G.S., Lin X., et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11 (2005) 4037-4043
60. Hoque M.O., Topaloglu O., Begum S., et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23 (2005) 6569-6575
61. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64 (2004) 1975-1986
62. Jones P.A., and Droller M.J. Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechanisms. Semin Urol 11 (1993) 177-192
63. Spruck III C.H., Ohneseit P.F., Gonzalez-Zulueta M., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54 (1994) 784-788
64. van Tilborg A.A., de Vries A., de Bont M., et al. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 9 (2000) 2973-2980
65. Brandau S., and Bohle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 39 (2001) 491-497
66. Duggan B.J., Gray S.B., McKnight J.J., et al. Oligoclonality in bladder cancer: The implication for molecular therapies. J Urol 171 (2004) 419-425
67. Paiss T., Wohr G., Hautmann R.E., et al. Some tumors of the bladder are polyclonal in origin. J Urol 167 (2002) 718-723
68. Hafner C., Knuechel R., Zanardo L., et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20 (2001) 4910-4915
69. Louhelainen J., Wijkstrom H., and Hemminki K. Allelic losses demonstrate monoclonality of multifocal bladder tumors. Int J Cancer 87 (2000) 522-527
70. Vriesema J.L., Aben K.K., Witjes J.A., et al. Superficial and metachronous invasive bladder carcinomas are clonally related. Int J Cancer 93 (2001) 699-702
71. Sokolova I.A., Halling K.C., Jenkins R.B., et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2 (2000) 116-123
72. Bubendorf L., Grilli B., Sauter G., et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116 (2001) 79-86
73. Sarosdy M.F., Schellhammer P., Bokinsky G., et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 168 (2002) 1950
74. Lee D.H., Yang S.C., Hong S.J., et al. Telomerase: A potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 4 (1998) 535-538
75. Ito H., Kyo S., Kanaya T., et al. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer. Clin Cancer Res 4 (1998) 2807-2810
76. Eissa S., Labib R.A., Mourad M.S., et al. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. Eur Urol 44 (2003) 687-694
77. Weikert S., Krause H., Wolff I., et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 117 (2005) 274-280
78. Sanchini M.A., Gunelli R., Nanni O., et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 294 (2005) 2052-2056
79. Smith S.D., Wheeler M.A., Plescia J., et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 285 (2001) 324-328
80. Weikert S., Christoph F., Schrader M., et al. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 116 (2005) 100-104
81. Wang H., Xi X., Kong X., et al. The expression and significance of survivin mRNA in urinary bladder carcinomas. J Cancer Res Clin Oncol 130 (2004) 487-490
82. Mao L., Schoenberg M.P., Scicchitano M., et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 271 (1996) 659-662
83. van Rhijn B.W., Lurkin I., Kirkels W.J., et al. Microsatellite analysis-DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: A phase II trial. Cancer 92 (2001) 768-775
84. Vaish M., Mandhani A., Mittal R.D., et al. Microsatellite instability as prognostic marker in bladder tumors: A clinical significance. BMC Urol 5 (2005) 2-9
85. Migaldi M., Sartori G., Rossi G., et al. Prevalence and prognostic significance of microsatellite alterations in young patients with bladder cancer. Mod Pathol 18 (2005) 1176-1186
86. Lee M.G., Kim H.Y., Byun D.S., et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61 (2001) 6688-6692
87. Maruyama R., Toyooka S., Toyooka K.O., et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61 (2001) 8659-8663
88. Catto J.W., Azzouzi A.R., Rehman I., et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 23 (2005) 2903-2910
89. Chan M.W., Chan L.W., Tang N.L., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8 (2002) 464-470
90. Dulaimi E., Uzzo R.G., Greenberg R.E., et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10 (2004) 1887-1893
91. Dyrskjot L., Thykjaer T., Kruhoffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33 (2003) 90-96
92. Dyrskjot L., Zieger K., Kruhoffer M., et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11 (2005) 4029-4036
93. de la Taille A., Buttyan R., Katz A.E., et al. Biomarkers of renal cell carcinoma. Past and future considerations. Urol Oncol 5 (2000) 139-148
94. Lam J.S., Shvarts O., Leppert J.T., et al. Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol 173 (2005) 1853-1862
95. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
96. Heidenreich A., Schrader A.J., and Varga Z. Basic science and research in renal cell carcinoma: From workbench to bedside. Curr Opin Urol 13 (2003) 457-462
97. Stolle C., Glenn G., Zbar B., et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12 (1998) 417-423
98. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
99. Yao M., Yoshida M., Kishida T., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94 (2002) 1569-1575
100. Velickovic M., Delahunt B., Storkel S., et al. VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res 61 (2001) 4815-4819
101. Brauch H., Weirich G., Brieger J., et al. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res 60 (2000) 1942-1948
102. Schraml P., Struckmann K., Hatz F., et al. VHL mutations and their correlation with tumor cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196 (2002) 186-193
103. Kim J.H., Jung C.W., Cho Y.H., et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13 (2005) 859-863
104. Kondo K., Yao M., Yoshida M., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 34 (2002) 58-68
105. Ashida S., Furihata M., Tanimura M., et al. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: Potential biomarkers for early diagnosis and postoperative metastatic status. J Urol 169 (2003) 2089-2093
106. Alimov A., Sundelin B., Wang N., et al. Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol 25 (2004) 179-185
107. Opavsky R., Pastorekova S., Zelnik V., et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics 33 (1996) 480-487
108. McKiernan J.M., Buttyan R., Bander N.H., et al. Expression of the tumor-associated gene MN: A potential biomarker for human renal cell carcinoma. Cancer Res 57 (1997) 2362-2365
109. Murakami Y., Kanda K., Tsuji M., et al. MN/CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 83 (1999) 743-747
110. McKiernan J.M., Buttyan R., Bander N.H., et al. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer 86 (1999) 492-497
111. Uemura H., Nakagawa Y., Yoshida K., et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81 (1999) 741-746
112. de la Taille A., Katz A., Cao Y., et al. Blood-based RT-PCR assays of MN/CA9 or PSMA: Clinical application in renal cancer patients. Urology 56 (2000) 393-398
113. Gilbert S.M., Mansukhani M., Benson M.C., et al. MN/CA9 expression predicts disease free survival in renal cell carcinoma. Proc Am Soc Clin Oncol 22 (2003) 418 [abstract]
114. Li G., Cuilleron M., Gentil-Perret A., et al. Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma. Clin Cancer Res 9 (2003) 6441-6446
115. Paul R., Ewing C.M., Robinson J.C., et al. Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Res 57 (1997) 2741-2748
116. Shimazui T., Yoshikawa K., Uemura H., et al. Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma. Int J Oncol 23 (2003) 1049-1054
117. Shimazui T., Yoshikawa K., Uemura H., et al. The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer 101 (2004) 963-968
118. Li G., Passebosc-Faure K., Gentil-Perret A., et al. Cadherin-6 gene expression in conventional renal cell carcinoma: A useful marker to detect circulating tumor cells. Anticancer Res 25 (2005) 377-381
119. Breault J.E., Shiina H., Igawa M., et al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res 11 (2005) 557-564
120. Orlando C., Gelmini S., Selli C., et al. Telomerase in urological malignancy. J Urol 166 (2001) 666-673
121. Yoshida K., Sakamoto S., Sumi S., et al. Telomerase activity in renal cell carcinoma. Cancer 83 (1998) 760-766
122. Mekhail T.M., Kawanishi-Tabata R., Tubbs R., et al. Renal cell carcinoma (RCC) and telomerase activity: Relationship to stage. Urol Oncol 21 (2003) 424-430
123. Segawa N., Gohji K., Azuma H., et al. Telomerase activity in renal cell carcinoma by modified telomeric repeat amplification protocol assay. Int J Urol 10 (2003) 153-159
124. Battagli C., Uzzo R.G., Dulaimi E., et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 63 (2003) 8695-8699
125. Cairns P. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann N Y Acad Sci 1022 (2004) 40-43
126. Dulaimi E., Ibanez de Caceres I., Uzzo R.G., et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 10 (2004) 3972-3979
127. Hoque M.O., Begum S., Topaloglu O., et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64 (2004) 5511-5517
128. Gonzalgo M.L., Eisenberger C.F., Lee S.M., et al. Prognostic significance of preoperative molecular serum analysis in renal cancer. Clin Cancer Res 8 (2002) 1878-1881
129. von Knobloch R., Hegele A., Brandt H., et al. High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 98 (2002) 889-894
130. Takahashi M., Rhodes D.R., Furge K.A., et al. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci USA 98 (2001) 9754-9759
131. Vasselli J.R., Shih J.H., Iyengar S.R., et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100 (2003) 6958-6963
132. Sultmann H., von Heydebreck A., Huber W., et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11 (2005) 646-655
133. Moch H., Presti Jr. J.C., Sauter G., et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56 (1996) 27-30
134. Mostofi F.K. Proceedings: Testicular tumors. Epidemiologic, etiologic, and pathologic features. Cancer 32 (1973) 1186-1201
135. Einhorn L.H. Treatment of testicular cancer: A new and improved model. J Clin Oncol 8 (1990) 1777-1781
136. Gori S., Porrozzi S., Roila F., et al. Germ cell tumors of the testis. Crit Rev Oncol Hematol 53 (2005) 141-164
137. Fleming I., Cooper J.S., Henson D.E., et al. AJCC cancer staging manual. 5th ed. (1998), Lippincott-Raven, Philadelphia (PA)
138. Bosl G.J., Dmitrovsky E., Reuter V.E., et al. Isochromosome of the short arm of chromosome 12: Clinically useful markers for male germ cell tumors. J Natl Cancer Inst 81 (1989) 1874-1878
139. Heidenreich A., Srivastava S., Moul J.W., et al. Molecular genetic parameters in pathogenesis and prognosis of testicular germ cell tumors. Eur Urol 37 (2000) 121-135
140. Roelofs H., Mostert M.C., Pompe K., et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol 157 (2000) 1155-1166
141. Bosl G.J., Ilson D.H., Rodriguez E., et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 86 (1994) 349-355
142. Meng F.J., Zhou Y., Giwercman A., et al. Fluorescence in situ hybridization analysis of chromosome 12 anomalies in semen cells from patients with carcinoma in situ of the testis. J Pathol 186 (1998) 235-239
143. Looijenga L.H., and Oosterhuis J.W. Clinical value of the X chromosome in testicular germ-cell tumours. Lancet 363 (2004) 6-8
144. Kawakami T., Okamoto K., Ogawa O., et al. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 363 (2004) 40-42
145. Hautkappe A.L., Lu M., Mueller H., et al. Detection of germ-cell tumor cells in the peripheral blood by nested reverse transcription-polymerase chain reaction for alpha-fetoprotein-messenger RNA and beta human chorionic gonadotropin-messenger RNA. Cancer Res 60 (2000) 3170-3174
146. Jensen M., Leffers H., Petersen J.H., et al. Frequent polymorphism of the mitochondrial DNA polymerase gamma gene (POLG) in patients with normal spermiograms and unexplained subfertility. Hum Reprod 19 (2004) 65-70
147. Nowak R., Zub R., Skoneczna I., et al. CAG repeat polymorphism in the DNA polymerase gamma gene in a Polish population: An association with testicular cancer risk. Ann Oncol 16 (2005) 1211-1212
148. Mayer F., Gillis A.J., Dinjens W., et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62 (2002) 2758-2760
149. Velasco A., Riquelme E., Schultz M., et al. Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther 3 (2004) 1152-1158
150. Koul S., McKiernan J.M., Narayan G., et al. Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer 3 (2004) 16-28
151. Rao P.H., Houldsworth J., Palanisamy N., et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 58 (1998) 4260-4263
152. Sugimura J., Foster R.S., Cummings O.W., et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res 10 (2004) 2368-2378